arrow
K

Kerry J. Savage

centre for lymphoid cancer and department of medical oncology
H指数:84
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LySeqST: A targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma

LySeqST:一种用于弥漫性大B细胞淋巴瘤稳健基因组分类的靶向测序检测方法

2026-04-170
OAAI
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses

IA期NLPHL患者的临床结局:全球NLPHL工作组(GLOW)回顾性分析

2026-04-160
OAAI
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

更正: Brentuximab vedotin联合化疗治疗一线系统性间变性大细胞淋巴瘤: 5年随访时ECHELON-2研究的亚组分析

2026-01-280
OAAI
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性弥漫性大B细胞淋巴瘤

2025-12-100
OAAI
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology

在高MYC/BCL2易位的弥漫大B细胞淋巴瘤中,进行剂量调整的EPOCH-R方案的群体推广,该淋巴瘤具有DLBCL形态。

2025-10-170
OAAI
Camidanlumab Tesirine in Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Camidanlumab Tesirine 在复发或难治性经典型霍奇金淋巴瘤中的应用:一项 II 期研究

2025-08-190
OAAI
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

brentuximab vedotin联合化疗用于一线系统性间变性大细胞淋巴瘤的治疗:ECHELON-2研究5年随访的亚组分析

2025-08-010
OAAI
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

高级别B细胞淋巴瘤,非其他特指类型:一项LLMPP研究。

2025-07-210
OAAI
Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma

体细胞IRF4突变和胸腺趋向性在原发性纵隔大B细胞淋巴瘤中的作用

Blood
IF23.1
2025-06-240
OA
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

纳武利尤单抗联合罗特利珠单抗治疗复发或进展性B细胞恶性肿瘤的RELATIVITY-022研究

2025-03-050
OA
The Phenotypic Landscape of Anaplastic Large Cell Lymphoma Supports a New Molecular Classification: An LLMPP Study

间变性大细胞淋巴瘤的表型景观支持新的分子分类: 一项LLMPP研究

2025-03-010
PRE
Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

使用多参数方法细化外周T细胞淋巴瘤的诊断亚型

2025-02-010
PRE
Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an LLMPP Study

根据EBV状态和MYC重排定义的浆细胞样淋巴瘤的生物与预后亚组——一项LLMPP研究

BLOOD
IF23.1
2024-11-050
PRE
Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

慢性淋巴细胞白血病(CLL)和小淋巴细胞淋巴瘤(SLL)中的里希特转化(RT):两个时代的比较

BLOOD
IF23.1
2024-11-050
PRE
CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

CSF2RB基因突变导致经典霍奇金淋巴瘤中细胞因子依赖性的获得性功能表型。

BLOOD
IF23.1
2024-11-050
PRE